Carmustine as a Supplementary Therapeutic Option for Glioblastoma: A Systematic Review and Meta-Analysis

Carmustine as a Supplementary Therapeutic Option for Glioblastoma: A Systematic Review and Meta-Analysis

Background: Glioblastoma (GBM) is the most aggressive type of primary malignant brain tumor. Carmustine is used by intravenous injection or local implantation in the resection cavity for gliomas, including GBMs. However, the therapeutic potential of carmustine is not well-recognized. This analysis a...

Full description

Bibliographic Details
Main Authors: Zhi-Ze Xiao, Ze-Fen Wang, Tian Lan, Wen-Hong Huang, Yu-Hang Zhao, Chao Ma, Zhi-Qiang Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Neurology
Subjects:
glioblastoma
carmustine (BCNU)
overall survival (OS)
meta-analysis
chemotherapy
Online Access:https://www.frontiersin.org/article/10.3389/fneur.2020.01036/full

Similar Items

Similar Items